Ethylenediaminetetra(methylenephosphonic acid) sodium  (Synonyms: EDTMP sodium)

Ethylenediaminetetramethylenephosphonic acid (EDTMP) sodium is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with ¹⁵³Sm and ¹⁷⁷Lu. Ethylenediaminetetramethylenephosphonic acid sodium is used to study palliative therapy for pain associated with multiple bone metastatic cancers^[1][2][3].

Ethylenediaminetetramethylenephosphonic acid sodium forms stable complexes with ¹⁵³Sm and ¹⁷⁷Lu, and EDTMP delivers and immobilizes them at bone metastatic lesions. The β or γ rays released during the decay of ¹⁵³Sm/¹⁷⁷Lu produce ionizing radiation locally at the lesions to kill tumor cells, thereby achieving the goal of relieving bone pain^[1][2][3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

546.03

C₆H₁₅N₂Na₅O₁₂P₄

7651-99-2

O=P(CN(CP(O)(O[Na])=O)CCN(CP(O)(O[Na])=O)CP(O)(O[Na])=O)(O[Na])O[Na]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Askari E, et al. ¹⁷⁷Lu-EDTMP for Metastatic Bone Pain Palliation: A Systematic Review and Meta-Analysis. Cancer Biother Radiopharm. 2021;36(5):383-390.

  [2]. Maini CL, et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31 Suppl 1:S171-S178.

  [3]. Holmes RA. [153Sm] EDTMP: a potential therapy for bone cancer pain. InSeminars in nuclear medicine 1992 Jan 1 (Vol. 22, No. 1, pp. 41-45). WB Saunders.